ZAZeinab Y. Abdallah

Zeinab Y. Abdallah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zeinab Y. Abdallah has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Ekram Fateen

    Biochemical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, 12622 Cairo, Egypt

    3 shared publications
  • Ekram Fateen

    Biochemical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt

    3 shared publications
  • Ghada Nour Eldeen

    Human Genetics and Genome Research Institute, Molecular Genetics and Enzymology Department, National Research Centre, Cairo, Egypt

    2 shared publications
  • Khaled Hamed

    Human Genetics and Genome Research Institute, Clinical Genetics Department, National Research Centre, Cairo, Egypt

    2 shared publications
  • Mona Ibrahim

    Biochemical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, 12622, Egypt

    2 shared publications
  • Mona M. Ibrahim

    Biochemical Genetics Department, National Research Centre, Giza, Egypt

    2 shared publications

Latest Publications

  • Open Access

    Evidence of the role of Midkine and Pleiotrophin in the pathogenesis of Familial Mediterranean Fever

    by Zeinab Y. Abdallah, Ghada Nour Eldeen, Mona F. Sokkar, Rania Fawzy Mahmoud Abdelkawy, Randa S. Lotfy, Shymaa H. Hussein, Khaled Hamed, Hala T. El-Bassyouni

    Familial Mediterranean Fever (FMF) is a chronic autoinflammatory illness that follows a pattern of periodic attacks; however, the majority of cases experience ongoing subclinical inflammation during the attack-free periods that could lead to the development of anemia, splenomegaly, heart disease, and the major complication, amyloidosis. Midkine/Pleiotrophin (MDK/PTN) are heparin-binding cytokines, with upregulated expression in various inflammatory and malignant diseases. Thus, the present research aims to identify the role of MDK and PTN in the pathogenesis of chronic inflammation and to explore the potential of both cytokines as new markers of subclinical inflammation in FMF. Blood samples from 30 FMF patients and 30 controls were collected to assess gene expression and protein levels of MDK and PTN by qRT-PCR and ELISA, respectively. Statistical correlation between different parameters and bioinformatic analysis to link the MEFV gene to the relevant genes was also performed. The expression of MDK and PTN genes was significantly higher in FMF children than in healthy subjects. Additionally, the serum level of MDK showed a fourfold increase in patients compared to controls ( p < 0.001). The levels of PTN were also higher in cases, but without reaching the significance level ( p = 0.096). MDK gene expression was inversely related to ESR level and positively correlated to serum level of MDK and anemia occurrence. Conclusion : Collectively, our results disclosed that Midkine could be identified as a useful clinical tool in diagnosing and managing systemic and subclinical inflammation in FMF cases, while Pleiotrophin might provide additional information on acute inflammatory processes. What is Known: • Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disorder characterized by recurrent bouts of systemic and acute inflammation. • Midkine and Pleiotrophin are heparin-binding growth factors often associated with inflammatory responses. What is New: • Midkine could be identified as a reliable clinical biomarker for both diagnosing and managing systemic and subclinical inflammatory phase in FMF patients. • Pleiotrophin might provide additional information on acute inflammatory processes.

  • Open Access

    Genetic insights and therapeutic implications in Egyptian patients with Fabry Disease

    by Ekram Fateen, Eman E.A. Mohammed, Nahla N. Abdel-Aziz, Zeniab Y. Abdallah, Rasha M. Elhossini, Mona Aglan

    BackgroundFabry disease (FD) is an X-linked lysosomal storage disorder resulting from pathogenic variants in the α-galactosidase (GLA) gene, leading to deficiency in “α-galactosidase A” (GLA) activity. This enzyme deficiency leads to progressive accumulation of glycosphingolipids in various tissues and organs. ObjectivesThis study aims to clinical, biochemical, and molecular diagnosis for three unrelated Egyptian families with Fabry disease.Patients and methods The GLA enzyme activity was measured in 3 males from 3 unrelated families. The GLA activity was measured by using the fluorogenic substrate “4-methylumbelliferyl-α-D-galactopyranoside” and the diagnosis of FD was established by GLA deficiency. The patients presented with variable renal, cardiac, ocular and dermatological manifestations. History and pedigree was done for 3 families. Molecular analysis of GLA gene was performed for 3 patients, the mother, two daughters and the sister of P1, the mother, wife and daughter of P2, and the mother, brother, and cousin of P3. Genetic tests by PCR of the gene-coding region followed by Sanger sequencing. Results We revealed 3 previously reported GLA variants in 3 Fabry families. Family 1, a nonsense variant c.627G>A, p.W209* was identified in patient 1 and in one of the patient’s daughters. In Family 2, a splice-site variant c.370-2A>G was detected in patient 2 and in his mother and daughter. In Family 3, a missense variant c.334C>T, p.R112C was detected in patient 3.Conclusion This study expands the molecular genetic spectrum of the GLA gene associated with Egyptian FD patients. Our findings highlighted the importance of early diagnosis, proper genetic counseling and therapy for FD patients. To the best of our knowledge, the present study is the first delineating the GLA variant profile in Egyptian FD patients. The patients are currently receiving Enzyme Replacement Therapy (ERT) at National Research Centre (NRC).

  • Open Access

    Relative Frequency of Metachromatic Leukodystrophy in Egypt: A Reference Laboratory Report

    by Ekram Fateen, Zeinab Y. Abdallah

    Background: Metachromatic leukodystrophy (MLD) is an autosomal recessive hereditary neurodegenerative disease caused by a deficiency in arylsulfatase A (ARSA) activity and belongs to the group of lysosomal storage diseases. A biochemical diagnosis of MLD is based on determining the residual ARSA activity in leukocytes, skin fibroblasts, and urine. This study documents our biochemical experience and estimates the relative frequency of MLD over 21 years (2001–2022). Methods: This study analyzed 4357 suspected cases of MLD in Egypt. The ARSA activity was spectrophotometrically determined in leukocytes in all the referred cases. Results: Of these 4357 referred cases, 577 (13%) possessed decreased ARSA activity, less than 10% of the low normal range (50–200 micromole/gram protein/hour (μmol/g protein/h), and 104 cases were diagnosed as having a pseudodeficiency in enzyme activity (<20–50% of low–normal ARSA activity). The prevalence of MLD was 1.6/100,000. Conclusions: A diagnosis of MLD in Egypt is based on enzyme activity levels and clinical suspicion; molecular analysis was performed in a few cases.


  • Open Access

    Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt

    by Ekram Fateen, Zeinab Y. Abdallah, Walaa S. Nazim, Mona Ibrahim, Amira Radwan


  • Open Access

    Clinical Implications of S100A12 and Resolvin D1 Serum Levels, and Related Genes in Children with Familial Mediterranean Fever

    by Zeinab Y. Abdallah, Mona Ibrahim, Manal M. Thomas, Hisham Megahed, Ghada Nour Eldeen, Khaled Hamed, Mohamed Fares, Mahmoud ElHefnawi, Hala T. El-Bassyouni

    The aim of this article was to study the role of S100A12 and resolvin D1-related genes and serum levels in the diagnosis and detection of subclinical inflammation in children with familial Mediterranean fever (FMF) during the quiescent stage of the disease. Seventy-eight children with FMF during the silent state and 60 healthy control were studied. Serum S100A12 and resolvin D1 were quantitatively measured using enzyme-linked immunosorbent assay. In addition, the levels of C-reactive protein, erythrocyte sedimentation rate, and hemoglobin were determined. The clinical severity was evaluated. The link between the Mediterranean fever (MEFV) gene and the genes related to the two studied biomarkers was also assessed. Correlation between S100A12 and resolvin D1 and the clinical severity was assessed. The mean serum levels of S100A12 and resolvin D1 were 847.4 and 793.3, respectively, which were highly significantly increased (p = 0.001) compared with the controls (324.3 and 235.1, respectively). The receiver operating characteristic curve test showed that S100A12 had a sensitivity of 97.4% and specificity of 80% with cutoff value of 529.5, while resolvin D1 showed a sensitivity of 100% and specificity of 50% with cutoff value of 231.2. A correlation was detected between the clinical severity and S100A12 and resolvin D1. This study delineated that S100A12 and resolvin D1 are sensitive biomarkers to detect the degree of inflammation in children with FMF during the silent period. Consequently, we recommend adjusting the colchicine dose to ameliorate the disease's symptoms and to improve the quality of life in these patients.


  • Open Access

    Prenatal genetic testing, counseling and follow-up of 33 Egyptian pregnant females with history of mucopolysaccharidoses

    by Khaled R. Gaber, Mona M. Ibrahim, Mona K. Farag, Zeinab Y. Abdallah, Sara H. Eldessouky, Ekram M. Fateen


  • Open Access

    Fifteen years experience: Egyptian metabolic lab

    by Ekram M. Fateen, Amr S. Gouda, Mona M. Ibrahim, Zeinab Y. Abdallah